Cost-Effectiveness Analysis Using Registry and Administrative Data

Health administrative databases and disease registries can serve as valuable data sources for decision modeling and cost-effectiveness analyses. In this chapter, we give an overview of administrative databases in Canada and discuss how data from multiple registries and administrative databases can be linked, analyzed, and combined with experimental data to fit a decision analytic model. We illustrate with two examples of cost-effectiveness analyses of genetic tests used in cancer diagnosis and treatment decisions.

[1]  S. Paik,et al.  Association between the 21-gene recurrence score assay and risk of locoregional recurrence in node-negative, estrogen receptor-positive breast cancer: results from NSABP B-14 and NSABP B-20. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  I. Bleiweiss,et al.  Lymphatic invasion, tumor size, and age are independent predictors of axillary lymph node metastases in women with T1 breast cancers. , 1999, Annals of surgery.

[3]  C. Stiller,et al.  Centralised treatment, entry to trials and survival. , 1994, British Journal of Cancer.

[4]  Xianglin L. Du,et al.  Population-based assessment of hospitalizations for toxicity from chemotherapy in older women with breast cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  Gregory S. Zaric,et al.  Cost‐Effectiveness Analysis, Health‐Care Policy, and Operations Research Models , 2010 .

[6]  K. Carriere,et al.  Outcomes and Costs Among Seniors Requiring Hospitalization for Community‐Acquired Pneumonia in Alberta , 2004, Journal of the American Geriatrics Society.

[7]  Hillner Be.  Basic principles of cost-effectiveness analysis. , 1987 .

[8]  W Wood,et al.  Selection bias in clinical trials. , 1985, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  Robert B Livingston,et al.  Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. , 2010, The Lancet. Oncology.

[10]  M. Drummond.  Experimental versus Observational Data in the Economic Evaluation of Pharmaceuticals , 1998, Medical decision making : an international journal of the Society for Medical Decision Making.

[11]  G. Naglie,et al.  Healthcare costs associated with prostate cancer: estimates from a population‐based study , 2010, BJU international.

[12]  Arno Floore,et al.  Gene expression profiling to identify the histogenetic origin of metastatic adenocarcinomas of unknown primary. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  M. Cronin,et al.  Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  G. Hortobagyi,et al.  Impact of selection process on response rate and long-term survival of potential high-dose chemotherapy candidates treated with standard-dose doxorubicin-containing chemotherapy in patients with metastatic breast cancer. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  J. Ayanian.  Using administrative data to assess health care outcomes. , 1999, European heart journal.

[16]  R. Lilford,et al.  Are randomized clinical trials good for us (in the short term)? Evidence for a "trial effect". , 2001, Journal of clinical epidemiology.

[17]  M. Cronin,et al.  A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. , 2004, The New England journal of medicine.

[18]  R. Willke,et al.  Good research practices for cost-effectiveness analysis alongside clinical trials: the ISPOR RCT-CEA Task Force report. , 2005, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[19]  A James O'Malley,et al.  Frequency and cost of chemotherapy-related serious adverse effects in a population sample of women with breast cancer. , 2006, Journal of the National Cancer Institute.

[20]  J. Zujewski,et al.  Trial assessing individualized options for treatment for breast cancer: the TAILORx trial. , 2008, Future oncology.

[21]  C. Bauch,et al.  Economic Appraisal of Ontario's Universal Influenza Immunization Program: A Cost-Utility Analysis , 2010, PLoS medicine.

[22]  M. Brackstone,et al.  Cost-effectiveness of a 21-gene recurrence score assay versus Canadian clinical practice in women with early-stage estrogen- or progesterone-receptor-positive, axillary lymph-node negative breast cancer , 2012, BMC Cancer.

[23]  C. Mackenzie,et al.  A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. , 1987, Journal of chronic diseases.

[24]  C. Marra,et al.  Cost Effectiveness of Herpes Zoster Vaccine in Canada , 2012, PharmacoEconomics.

[25]  C. Shapiro,et al.  Side effects of adjuvant treatment of breast cancer. , 2001, The New England journal of medicine.

[26]  Jing Jing Li,et al.  Using effectiveness and cost-effectiveness to make drug coverage decisions: a comparison of Britain, Australia, and Canada. , 2009, JAMA.

[27]  M. Levine,et al.  Clinical practice guidelines for the care and treatment of breast cancer: adjuvant systemic therapy for node-negative breast cancer (summary of the 2001 update). , 2001, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[28]  D. Cameron,et al.  Docetaxel in combination with doxorubicin and cyclophosphamide as adjuvant treatment for early node-positive breast cancer: a cost-effectiveness and cost-utility analysis. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  M. Levine,et al.  Clinical practice guidelines for the care and treatment of breast cancer: adjuvant systemic therapy for node-positive breast cancer (summary of the 2001 update). The Steering Committee on Clinical Practice Guidelines for the Care and Treatment of Breast Cancer. , 2001, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[30]  F. Monzon,et al.  Identification of tissue of origin in carcinoma of unknown primary with a microarray-based gene expression test , 2010, Diagnostic pathology.

[31]  D. Cameron,et al.  Edinburgh Research Explorer Health economics in drug development: efficient research to inform healthcare funding decisions , 2022 .

[32]  J. Pollack,et al.  Interlaboratory performance of a microarray-based gene expression test to determine tissue of origin in poorly differentiated and undifferentiated cancers. , 2008, The Journal of molecular diagnostics : JMD.

[33]  Martina Garau,et al.  Comparing estimates of cost effectiveness submitted to the National Institute for Clinical Excellence (NICE) by different organisations: retrospective study , 2004, BMJ : British Medical Journal.

[34]  L. Lix,et al.  Canadian breast cancer guidelines: Have they made a difference? , 2007, Canadian Medical Association Journal.

[35]  B. Manns,et al.  Optimizing the use of prescription drugs in Canada through the Common Drug Review , 2008, Canadian Medical Association Journal.

[36]  S. Hill,et al.  Drug prices and value for money: the Australian Pharmaceutical Benefits Scheme. , 2005, JAMA.

[37]  Karl Claxton,et al.  Addressing Adoption and Research Design Decisions Simultaneously , 2011, Medical decision making : an international journal of the Society for Medical Decision Making.

[38]  J. Mumpower,et al.  Physicians' Diagnostic Judgments and Treatment Decisions for Acute Otitis Media in Children , 1998, Medical decision making : an international journal of the Society for Medical Decision Making.